文献速递甲状腺疾病

多激酶抑制剂治疗无症状放射性碘难治性分化型甲状腺癌:全球非干预研究(RIFTOS MKI)

Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
PubMed 文献 · Thyroid · 2022-01-01

这项国际、前瞻性、开放标签、非干预性队列研究(NCT02303444)纳入647例无症状、进展性放射性碘难治性分化型甲状腺癌患者,比较研究入组时决定启用多激酶抑制剂(MKI)者(队列1,n=169)与决定不启用者(队列2,n=478)。总体中位至症状进展时间为55.4个月,队列1为55.4个月,队列2为51.4个月;研究结论认为该真实世界研究为观察或接受MKI治疗患者的结局提供了有价值的信息。

要点

  • 总体中位至症状进展时间55.4个月,队列1为55.4个月,队列2为51.4个月
  • 总体64.5%的患者至症状进展时间≥36个月,队列1为59.5%,队列2为66.4%
  • 索拉非尼治疗者中70%发生剂量调整、35%剂量降低、89%出现至少1例治疗中出现的不良事件

核心结论

  • 这项真实世界研究为无症状、进展性放射性碘难治性分化型甲状腺癌患者在观察或接受MKI治疗下的结局提供了有价值的信息。
  • 全分析集中至症状进展时间反映了MKI时代放射性碘难治性分化型甲状腺癌患者的当前预后。

研究设计与样本

  • 国际、前瞻性、开放标签、非干预性队列研究(NCT02303444)。
  • 纳入无症状、进展性放射性碘难治性分化型甲状腺癌患者,要求至少1个病灶直径≥1 cm且预期寿命≥6个月。
  • 是否启用MKI由治疗医师自行决定。
  • 主要终点为自研究入组起的至症状进展时间。
  • 评估两个队列:研究入组时决定启动MKI者(队列1)与研究入组时决定不启动MKI者(队列2),两队列进行描述性比较。

主要发现

  • 全分析集共647例患者,中位观察时长35.5个月(范围<1-59.4)。
  • 344例接受MKI治疗的患者中,209例曾接受索拉非尼,191例曾接受仑伐替尼,19例曾接受另一种MKI。
  • 总体中位至症状进展时间为55.4个月(四分位距18.6-不可估计),队列1(n=169)为55.4个月(四分位距15.2-不可估计),队列2(n=478)为51.4个月(四分位距20.0-不可估计)。
  • 至症状进展时间≥36个月者总体占64.5%,队列1占59.5%,队列2占66.4%。
  • 自被归类为放射性碘难治起的中位总生存期为167个月;自MKI治疗开始的中位无进展生存期为19.2个月,自索拉非尼治疗开始为16.7个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Sorafenib and lenvatinib are multikinase inhibitors (MKIs) approved for patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). There is no consensus on when to initiate MKI treatment. The objective of this study was to evaluate time to symptomatic progression (TTSP) in patients with RAI-R DTC for whom the decision to treat with an MKI was made at study entry. Methods: International, prospective, open-label, noninterventional cohort study (NCT02303444). Eligible patients had asymptomatic progressive RAI-R DTC, with ≥1 lesion ≥1 cm in diameter and life expectancy ≥6 months. The decision to treat with an MKI was at the treating physician's discretion. Primary endpoint was TTSP from study entry. Two cohorts were evaluated: patients for whom a decision to initiate an MKI was made at study entry (Cohort 1) and patients for whom there was a decision not to initiate an MKI at study entry (Cohort 2). Cohorts were compared descriptively. Results: The full analysis set (FAS) comprised 647 patients. The median duration of observation was 35.5 months (range <1-59.4). Of 344 MKI-treated patients, 209 received sorafenib, 191 received lenvatinib, and 19 received another MKI at some point. Median TTSP was 55.4 months (interquartile range [IQR] 18.6-not estimable [NE]) overall, 55.4 months (IQR 15.2-NE) in Cohort 1 (n = 169), and 51.4 months (IQR 20.0-NE) in Cohort 2 (n = 478). TTSP ≥36 months was achieved in 64.5% of patients overall, 59.5% of patients in Cohort 1, and 66.4% of patients in Cohort 2. Median overall survival from classification as RAI-R was 167 months and median progression-free survival from start of MKI therapy was 19.2 months and from start of sorafenib therapy 16.7 months. Among sorafenib-treated patients, 70% had dose modifications, 35% had a dose reduction, 89% experienced ≥1 treatment-emergent adverse event (TEAE), and 82% experienced ≥1 drug-related TEAE. Conclusions: This real-world study provides valuable insight into outcomes in patients with asymptomatic, progressive RAI-R DTC under observation or receiving MKI treatment. TTSP in the FAS provides insight into the current prognosis for patients with RAI-R DTC in the era of MKIs. Registration: NCT02303444.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Brose MS, Smit JWA, Lin CC, et al. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI). Thyroid. 2022. PMID: 35950621. doi:10.1089/thy.2022.0061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。